Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Fahrleitner-Pammer, A; Papaioannou, N; Gielen, E; Feudjo Tepie, M; Toffis, C; Frieling, I; Geusens, P; Makras, P; Boschitsch, E; Callens, J; Anastasilakis, AD; Niedhart, C; Resch, H; Kalouche-Khalil, L; Hadji, P.
Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.
Arch Osteoporos. 2017; 12(1):58-58
Doi: 10.1007/s11657-017-0351-2
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Fahrleitner-Pammer Astrid
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Persistence with osteoporosis therapy is vital for fracture prevention. This non-interventional study of postmenopausal women receiving denosumab in Germany, Austria, Greece, and Belgium found that persistence with denosumab remains consistently high after 24 months in patients at high risk of fracture. Continued persistence with osteoporosis therapy is vital for fracture prevention. This non-interventional study of clinical practice evaluated medication-taking behavior of postmenopausal women receiving denosumab in Germany, Austria, Greece, and Belgium and factors influencing persistence. Subcutaneous denosumab (60 mg every 6 months) was assigned according to prescribing information and local guidelines before and independently of enrollment; outcomes were recorded during routine practice for up to 24 months. Persistence was defined as receiving the subsequent injection within 6 months + 8 weeks of the previous injection and adherence as administration of subsequent injections within 6 months ± 4 weeks of the previous injection. Medication coverage ratio (MCR) was calculated as the proportion of time a patient was covered by denosumab. Associations between pre-specified baseline covariates and 24-month persistence were assessed using multivariable logistic regression. The 24-month analyses included 1479 women (mean age 66.3-72.5 years) from 140 sites; persistence with denosumab was 75.1-86.0%, adherence 62.9-70.1%, and mean MCR 87.4-92.4%. No covariate had a significant effect on persistence across all four countries. For three countries, a recent fall decreased persistence; patients were generally older with chronic medical conditions. In some countries, other covariates (e.g., older age, comorbidity, immobility, and prescribing reasons) decreased persistence. Adverse drug reactions were reported in 2.3-6.9% patients. Twenty-four-month persistence with denosumab is consistently high among postmenopausal women in Europe and may be influenced by patient characteristics. Further studies are needed to identify determinants of low persistence.
- Find related publications in this database (using NLM MeSH Indexing)
- Age Factors -
- Aged -
- Bone Density Conservation Agents - administration & dosage
- Bone Density Conservation Agents - adverse effects
- Bone Density Conservation Agents - therapeutic use
- Comorbidity -
- Denosumab - administration & dosage
- Denosumab - adverse effects
- Denosumab - therapeutic use
- Drug Administration Schedule -
- Europe - epidemiology
- Female -
- Humans -
- Injections, Subcutaneous -
- Medication Adherence - statistics & numerical data
- Middle Aged -
- Osteoporosis, Postmenopausal - drug therapy
- Osteoporosis, Postmenopausal - epidemiology
- Osteoporotic Fractures - epidemiology
- Osteoporotic Fractures - prevention & control
- Prospective Studies -
- Risk Factors -
- Find related publications in this database (Keywords)
- Adherence
- Compliance
- Denosumab
- Non-interventional study
- Osteoporosis
- Persistence